Loading...

Razelle Kurzrock

Title(s)Professor, Medicine
SchoolHealth Sciences
Address9500 Gilman Drive #0658
La Jolla CA 92093
Phone858-246-1102
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Role of ultra-violet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol. 2020 Jun 12. Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. PMID: 32530570.
      View in: PubMed   Mentions:    Fields:    
    2. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020 Jun 04; 5(11). Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. PMID: 32493840.
      View in: PubMed   Mentions:    Fields:    
    3. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Crit Rev Oncol Hematol. 2020 May 20; 151:102990. Li AM, Boichard A, Felip E, Kurzrock R. PMID: 32485428.
      View in: PubMed   Mentions:    Fields:    
    4. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 May 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031.
      View in: PubMed   Mentions:    Fields:    
    5. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 May 15; 26(10):2434. Patel SP, Othus M, Chae YK, Kurzrock R. PMID: 32414761.
      View in: PubMed   Mentions:    Fields:    
    6. Precision oncology: the intention-to-treat analysis fallacy. Eur J Cancer. 2020 May 15; 133:25-28. Sicklick JK, Kato S, Okamura R, Kurzrock R. PMID: 32422506.
      View in: PubMed   Mentions:    Fields:    
    7. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. PMID: 32337094.
      View in: PubMed   Mentions:
    8. ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Ann Surg Oncol. 2020 Apr 17. Baumgartner JM, Riviere P, Kurzrock R. PMID: 32303875.
      View in: PubMed   Mentions:    Fields:    
    9. Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. Mol Oncol. 2020 Jun; 14(6):1242-1251. Bieg-Bourne CC, Okamura R, Kurzrock R. PMID: 32187847.
      View in: PubMed   Mentions:    Fields:    
    10. Snapshot: Trial Types in Precision Medicine. Cell. 2020 Apr 02; 181(1):208-208.e1. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. PMID: 32243791.
      View in: PubMed   Mentions:    Fields:    
    11. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020 Jun; 86:102019. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. PMID: 32251926.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors. J Am Acad Dermatol. 2020 Feb 25. Cohen PR, Kurzrock R. PMID: 32109540.
      View in: PubMed   Mentions:    Fields:    
    13. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584.
      View in: PubMed   Mentions:
    14. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med. 2020 02 17; 12(1):16. Adashek JJ, Kato S, Lippman SM, Kurzrock R. PMID: 32066498.
      View in: PubMed   Mentions:    Fields:    
    15. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 Apr; 85(4):673-683. Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM, Ellis C, Ibrahim N, Yan L. PMID: 32062691.
      View in: PubMed   Mentions:    Fields:    
    16. New drug approvals in oncology. Nat Rev Clin Oncol. 2020 03; 17(3):140-146. Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV. PMID: 32020042.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020 Mar; 7(3):e209-e217. van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R. PMID: 32027862.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    18. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020 Feb; 8(1). Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. PMID: 32111729.
      View in: PubMed   Mentions:    Fields:    
    19. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 Jun 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524.
      View in: PubMed   Mentions:    Fields:    
    20. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 May 15; 26(10):2290-2296. Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. PMID: 31969335.
      View in: PubMed   Mentions: 1     Fields:    
    21. Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology. 2020; 9(1):1710052. Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R. PMID: 32002305.
      View in: PubMed   Mentions:
    22. The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. Cancers (Basel). 2020 Jan 09; 12(1). Boichard A, Richard SB, Kurzrock R. PMID: 31936627.
      View in: PubMed   Mentions:
    23. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020 01 09; 180(1):9-14. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. PMID: 31951522.
      View in: PubMed   Mentions:    Fields:    
    24. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. PMID: 31888672.
      View in: PubMed   Mentions:    Fields:    
    25. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Mar 15; 26(6):1237-1246. Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. PMID: 31822497.
      View in: PubMed   Mentions:    Fields:    
    26. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. PMID: 32067683.
      View in: PubMed   Mentions: 1     Fields:    
    27. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019 12 04; 12(1):130. Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. PMID: 31801585.
      View in: PubMed   Mentions: 1     Fields:    
    28. Targeting fusions for improved outcomes in oncology treatment. Cancer. 2020 Mar 15; 126(6):1315-1321. Nikanjam M, Okamura R, Barkauskas DA, Kurzrock R. PMID: 31794076.
      View in: PubMed   Mentions:    Fields:    
    29. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2019 Nov 20. Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. PMID: 31748338.
      View in: PubMed   Mentions:    Fields:    
    30. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2020 Feb; 25(2):94-98. Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. PMID: 32043794.
      View in: PubMed   Mentions: 1     Fields:    
    31. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Oncologist. 2020 Feb; 25(2):e386-e390. Saunders IM, Goodman AM, Kurzrock R. PMID: 32043767.
      View in: PubMed   Mentions:    Fields:    
    32. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Int J Cancer. 2020 Jun 01; 146(11):3087-3097. Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R. PMID: 31479512.
      View in: PubMed   Mentions:    Fields:    
    33. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019 10 01; 30(10):1647-1652. Kurzrock R, Gurski LA, Carlson RW, Ettinger DS, Horwitz SM, Kumar SK, Million L, von Mehren M, Benson AB. PMID: 31373348.
      View in: PubMed   Mentions: 1     Fields:    
    34. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2019 10 01; 30(10):1675. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. PMID: 31408092.
      View in: PubMed   Mentions:    Fields:    
    35. Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. Cancer Biol Ther. 2020; 21(1):95-100. Li AM, Boichard A, Kurzrock R. PMID: 31564192.
      View in: PubMed   Mentions:    Fields:    
    36. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15; 26(6):1247-1257. Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. PMID: 31527168.
      View in: PubMed   Mentions:    Fields:    
    37. Phase I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol. 2019 12; 16(12):773-778. Adashek JJ, LoRusso PM, Hong DS, Kurzrock R. PMID: 31477881.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019 Oct; 7(10):1570-1573. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. PMID: 31405947.
      View in: PubMed   Mentions:    Fields:    
    39. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. PMID: 31363003.
      View in: PubMed   Mentions: 2     Fields:    
    40. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. Mol Cancer Ther. 2019 10; 18(10):1852-1862. Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R. PMID: 31320401.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020 01 15; 146(2):566-576. Mardinian K, Okamura R, Kato S, Kurzrock R. PMID: 31199507.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    42. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18; 10(40):4018-4025. Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. PMID: 31258846.
      View in: PubMed   Mentions:    Fields:    
    43. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484. Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. PMID: 31186313.
      View in: PubMed   Mentions: 1     Fields:    
    44. Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. J Immunother Cancer. 2019 05 22; 7(1):130. Adashek JJ, Junior PNA, Galanina N, Kurzrock R. PMID: 31113482.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    45. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther. 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. PMID: 31011205.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    47. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 05; 25(5):744-750. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. PMID: 31011206.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    48. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990.
      View in: PubMed   Mentions:    Fields:    
    49. Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Rep. 2019 Apr; 5(4):312-316. Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R. PMID: 30989098.
      View in: PubMed   Mentions:
    50. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Mol Cancer Ther. 2019 05; 18(5):1001-1011. Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R. PMID: 30926636.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    51. Immune Escape of AML Cells after Transplantation. N Engl J Med. 2019 03 28; 380(13):1289. Goodman AM, Kurzrock R. PMID: 30917272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 04; 20(4):518-530. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. PMID: 30857956.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    53. Novel patterns of response under immunotherapy. Ann Oncol. 2019 03 01; 30(3):385-396. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C. PMID: 30657859.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    54. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 02 01; 7(1):27. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. PMID: 30709424.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    55. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precis Oncol. 2019; 3. Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R. PMID: 31032472.
      View in: PubMed   Mentions:
    56. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253.
      View in: PubMed   Mentions:
    57. Identification of targets for prostate cancer immunotherapy. Prostate. 2019 04; 79(5):498-505. Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. PMID: 30614027.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. PMID: 30347019.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    59. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer. 2019 04 01; 125(7):1185-1199. Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R. PMID: 30582752.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    60. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019; 8(3):1550341. Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. PMID: 30723579.
      View in: PubMed   Mentions:
    61. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461.
      View in: PubMed   Mentions:
    62. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast. 2019 Apr; 44:29-32. Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S. PMID: 30609392.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1a antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2019; 8(3):1551651. Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J. PMID: 30723583.
      View in: PubMed   Mentions:
    64. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol Cancer Ther. 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    65. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus. 2018 Nov 26; 10(11):e3634. Nikanjam M, Wing J, Capparelli E, Kurzrock R. PMID: 30705793.
      View in: PubMed   Mentions:
    66. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 11 16; 6(1):119. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. PMID: 30446007.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    67. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. PMID: 30637364.
      View in: PubMed   Mentions:
    68. ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis. Ann Surg Oncol. 2018 12; 25(Suppl 3):772-773. Baumgartner JM, Kurzrock R. PMID: 30421042.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. An avatar for precision cancer therapy. Nat Biotechnol. 2018 11 09; 36(11):1053-1055. Kato S, Kurzrock R. PMID: 30412185.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. PMID: 30383888.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    71. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2018 11 01; 29(11):2192-2199. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. PMID: 30219896.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    72. The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. Oncologist. 2019 01; 24(1):1-3. Subbiah V, Kurzrock R. PMID: 30352943.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    73. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018 12 15; 24(24):6248-6256. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. PMID: 30348637.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. PMID: 30339520.
      View in: PubMed   Mentions: 1     Fields:    
    75. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019; 20(2):219-226. Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R. PMID: 30339521.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. Front Oncol. 2018; 8:435. Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB. PMID: 30386736.
      View in: PubMed   Mentions:
    77. Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). Cancer Biol Ther. 2019; 20(3):247-251. Galanina N, Kurzrock R. PMID: 30307363.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. Integr Cancer Ther. 2018 12; 17(4):1012-1015. Jardim DL, de Melo Gagliato D, Kurzrock R. PMID: 30229677.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer. 2018 10 15; 124(20):4080-4089. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. PMID: 30204251.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    80. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018 10; 6(10):1129-1135. Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. PMID: 30194084.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    81. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. PMID: 30181172.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    82. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    83. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. PMID: 30139837.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018 08 03; 19(8):664-668. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. PMID: 29565699.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. PMID: 30148248.
      View in: PubMed   Mentions:
    86. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. PMID: 29989021.
      View in: PubMed   Mentions:    Fields:    
    87. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Ann Surg Oncol. 2018 Aug; 25(8):2400-2408. Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R. PMID: 29948422.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    88. MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. J Hematol Oncol. 2018 06 04; 11(1):76. Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R. PMID: 29866143.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    89. Reply to J.J. Tao et al. J Clin Oncol. 2018 08 10; 36(23):2451. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. PMID: 29856693.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Cancer research in the United States: A critical review of current status and proposal for alternative models. Cancer. 2018 07 15; 124(14):2881-2889. Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J. PMID: 29757456.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. PMID: 29695765.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    92. Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease. Oncology (Williston Park). 2018 04 15; 32(4):150-1, 163. Kurzrock R, Kato S. PMID: 29684227.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. The importance of greater speed in drug development for advanced malignancies. Cancer Med. 2018 05; 7(5):1824-1836. Stewart DJ, Stewart AA, Wheatley-Price P, Batist G, Kantarjian HM, Schiller J, Clemons M, Bradford JP, Gillespie L, Kurzrock R. PMID: 29601671.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050. Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. PMID: 29551775.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    95. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist. 2018 05; 23(5):586-593. Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. PMID: 29487225.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Mol Cancer Ther. 2018 05; 17(5):1114-1122. Ikeda S, Lim JS, Kurzrock R. PMID: 29483209.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    97. TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget. 2018 Mar 06; 9(18):14306-14310. Chang GH, Kurzrock R, Tran L, Schwaederle M, Hoh CK. PMID: 29581845.
      View in: PubMed   Mentions:    Fields:    
    98. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clin Cancer Res. 2018 04 15; 24(8):1881-1890. Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. PMID: 29363525.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    99. Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends Cancer. 2018 02; 4(2):101-109. Subbiah V, Kurzrock R. PMID: 29458960.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    100. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. J Clin Oncol. 2018 02 20; 36(6):536-542. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. PMID: 29320312.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    101. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405.
      View in: PubMed   Mentions:
    102. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. 2018 03 15; 124(6):1288-1296. Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. PMID: 29211306.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    103. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res. 2018 04 15; 24(8):1785-1794. Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. PMID: 29212781.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    104. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. Mol Cancer Ther. 2017 Dec; 16(12):2645-2655. Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ. PMID: 29203694.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16; 171(5):982-986. Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI. PMID: 29149611.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    106. Molecular Tumor Boards: Realizing Precision Oncology Therapy. Clin Pharmacol Ther. 2018 02; 103(2):206-209. Patel M, Kato SM, Kurzrock R. PMID: 29134641.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    107. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. Mol Cancer Ther. 2018 01; 17(1):297-305. Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R. PMID: 29133621.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    108. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 2018 Jan; 62:50-60. Krishnamurthy N, Kurzrock R. PMID: 29169144.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    109. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 11; 86:296-304. Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. PMID: 29059635.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    110. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. Oncologist. 2018 02; 23(2):171-178. Kato S, Kurasaki K, Ikeda S, Kurzrock R. PMID: 29038235.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    111. Genomics of Immunotherapy-Associated Hyperprogressors-Response. Clin Cancer Res. 2017 10 15; 23(20):6376. Kato S, Kurzrock R. PMID: 29030333.
      View in: PubMed   Mentions: 3     Fields:    
    112. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    113. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Res. 2017 11 15; 77(22):6313-6320. Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. PMID: 28939679.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    114. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. PMID: 29082359.
      View in: PubMed   Mentions:
    115. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017 08 30; 16(1):149. Khemlina G, Ikeda S, Kurzrock R. PMID: 28854942.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    116. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimalsCells
    117. BRAF mutation as a novel driver of eosinophilic cystitis. Cancer Biol Ther. 2017 Sep 02; 18(9):655-659. Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. PMID: 28829677.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    118. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    119. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    120. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. Eur J Cancer. 2017 09; 83:229-236. Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ. PMID: 28755607.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    121. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Jul 20. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. PMID: 28729355.
      View in: PubMed   Mentions: 1     Fields:    
    122. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 2017 09; 83:80-87. Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R. PMID: 28728050.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw. 2017 07; 15(7):863-866. Kato S, Subbiah V, Kurzrock R. PMID: 28687573.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    124. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Sep 15; 8(40):67782-67789. Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. PMID: 28978071.
      View in: PubMed   Mentions: 4     Fields:    
    125. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 2017; 6(8):e1338997. Nikanjam M, Patel H, Kurzrock R. PMID: 28920006.
      View in: PubMed   Mentions:
    126. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017 08 15; 77(16):4238-4246. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. PMID: 28642281.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    127. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    128. Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist. 2017 08; 22(8):881-882. Subbiah V, Kurzrock R. PMID: 28550030.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    129. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    130. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. JAMA Dermatol. 2017 05 01; 153(5):449-452. Patel M, Ikeda S, Pilat SR, Kurzrock R. PMID: 28241173.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Mol Cancer Ther. 2017 05; 16(5):948-955. Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R. PMID: 28468865.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    132. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041.
      View in: PubMed   Mentions:
    133. Polycystic ovary syndrome in men. Med Hypotheses. 2017 06; 103:64. Cohen PR, Kurzrock R. PMID: 28571814.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist. 2017 05; 22(5):576-584. Nikanjam M, Liu S, Yang J, Kurzrock R. PMID: 28424323.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    135. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R. PMID: 28420725.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    136. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017 08 01; 23(15):4027-4034. Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. PMID: 28377484.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    137. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. PMID: 27893038.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    138. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    139. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017 03; 36(1):179-190. Khagi Y, Kurzrock R, Patel SP. PMID: 27873079.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    140. Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. Cancer Treat Rev. 2017 Apr; 55:10-15. Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ. PMID: 28279895.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    141. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 10; 35(5):616-626. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. PMID: 28194539.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    142. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. Mol Cancer Ther. 2017 02; 16(2):265-272. Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. PMID: 28159915.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    143. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology. 2017; 6(3):e1284719. Boichard A, Tsigelny IF, Kurzrock R. PMID: 28405512.
      View in: PubMed   Mentions:
    144. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. PMID: 28103611.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    145. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Mar 23; 129(12):1646-1657. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. PMID: 28087540.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    146. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 12 14; 14(1):339. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. PMID: 27974047.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    147. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2017 Mar 01; 23(5):1137-1148. Kurzrock R, Stewart DJ. PMID: 27940520.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    148. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors. JAMA Oncol. 2016 Dec 01; 2(12):1565-1573. Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. PMID: 27388585.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    149. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. PMID: 27852698.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    150. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev. 2017 Jan; 52:12-21. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. PMID: 27883925.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    151. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    152. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. PMID: 27273579.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    153. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391.
      View in: PubMed   Mentions:
    154. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. PMID: 27599876.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    155. Targeted therapies: What have we learned from SHIVA? Nat Rev Clin Oncol. 2016 12; 13(12):719-720. Le Tourneau C, Kurzrock R. PMID: 27725677.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    156. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. PMID: 27589687.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    157. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017 04 15; 23(8):1988-1997. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. PMID: 27683183.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    158. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. PMID: 27486883.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    159. Bringing Blood-Based Molecular Testing to the Clinic. Clin Cancer Res. 2016 Nov 15; 22(22):5400-5402. Janku F, Kurzrock R. PMID: 27663595.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    160. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget. 2016 Aug 16; 7(33):53037-53046. Jardim DL, Schwaederle M, Hong DS, Kurzrock R. PMID: 27419632.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    161. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 08 15; 30(8):705-8, 710, 712. Goodman AM, Choi M, Wang L, Kurzrock R. PMID: 27535668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    162. Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther. 2016 10; 15(10):2498-2507. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27507853.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    163. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. PMID: 27466356.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    164. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 2016 Nov 01; 139(9):2135-41. Nikanjam M, Liu S, Kurzrock R. PMID: 27389805.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    165. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 08; 15(8):1781-91. Choi M, Kipps T, Kurzrock R. PMID: 27413114.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    166. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol. 2016 Aug; 78(2):427-32. Lam LH, Capparelli EV, Kurzrock R. PMID: 27372908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    167. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience. 2016; 3(5-6):164-72. Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F. PMID: 27489863.
      View in: PubMed   Mentions:
    168. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 06; 35(2):263-75. Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. PMID: 26857926.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    169. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016 Jun 01; 2(6):719-20. Subbiah V, Kurzrock R. PMID: 27078832.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    170. Health policy: The right to try is embodied in the right to die. Nat Rev Clin Oncol. 2016 07; 13(7):399-400. Cohen-Kurzrock BA, Cohen PR, Kurzrock R. PMID: 27217273.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    171. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. PMID: 27207774.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    172. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. PMID: 27197177.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    173. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. PMID: 27185373.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    174. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 07; 15(7):1682-90. Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27196769.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    175. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. PMID: 26933802.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    176. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget. 2016 Apr 26; 7(17):23454-67. Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. PMID: 26981779.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    177. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Arch Dermatol Res. 2016 Jul; 308(5):357-65. Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. PMID: 27098388.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    178. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. PMID: 27085994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    179. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 2016 Apr 12; 7(15):20293-304. Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. PMID: 26934122.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    180. My personal experiences at the BEST Medical Center: A day in the clinic-the morning. Clin Dermatol. 2016 May-Jun; 34(3):422-5. Cohen PR, Kurzrock R. PMID: 27265082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    181. My personal experiences at the BEST Medical Center: A day in the clinic-the afternoon. Clin Dermatol. 2016 Jul-Aug; 34(4):517-20. Cohen PR, Kurzrock R. PMID: 27343967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    182. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 08; 108(8). Kato S, Lippman SM, Flaherty KT, Kurzrock R. PMID: 27059373.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    183. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71. Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. PMID: 27044938.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    184. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. PMID: 26994910.
      View in: PubMed   Mentions: 1     Fields:    
    185. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 04; 15(4):533-47. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. PMID: 27009213.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    186. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016 Apr; 3(4):e163-75. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. PMID: 27063975.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    187. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016 Mar 08; 7(10):11310-20. Liu S, Nikanjam M, Kurzrock R. PMID: 26824502.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    188. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. PMID: 26848768.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    189. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs R D. 2016 Mar; 16(1):45-52. Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. PMID: 26689566.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    190. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001. Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. PMID: 26912651.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    191. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. PMID: 26873727.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    192. Click chemistry, 3D-printing, and omics: the future of drug development. Oncotarget. 2016 Jan 19; 7(3):2155-8. Kurzrock R, Stewart DJ. PMID: 26734837.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    193. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. PMID: 26698868.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    194. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015 Dec 15; 6(40):43127-34. Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. PMID: 26503473.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    195. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy. 2016; 8(1):17-26. Fajgenbaum DC, Kurzrock R. PMID: 26634298.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    196. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015 Dec; 16(16):e579-80. Tsimberidou AM, Kurzrock R. PMID: 26678197.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    197. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Cancer Metastasis Rev. 2015 Dec; 34(4):547-61. Munoz J, Wheler J, Kurzrock R. PMID: 25543191.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    198. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    199. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. PMID: 26582900.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    200. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015 Nov; 13(11):1337-46. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. PMID: 26553764.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    201. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    202. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. PMID: 26474549.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    203. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. Clin Cancer Res. 2015 Oct 15; 21(20):4561-8. Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. PMID: 26473192.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    204. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015 Oct 06; 6(30):30408-19. van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. PMID: 26327301.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    205. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. PMID: 26330075.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    206. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. PMID: 26164085.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    207. Targeted Inhibitors: Novel Strategies for Response Optimization. Semin Oncol. 2015 Dec; 42(6):773-4. Kurzrock R. PMID: 26615124.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    208. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec; 42(6):832-48. Falchook GS, Bastida CC, Kurzrock R. PMID: 26615129.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    209. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Semin Oncol. 2015 Dec; 42(6):863-75. Liu S, Kurzrock R. PMID: 26615131.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    210. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. PMID: 26247885.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    211. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. PMID: 26392102.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCTClinical Trials
    212. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. PMID: 26378224.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    213. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. PMID: 26405159.
      View in: PubMed   Mentions:    Fields:    
    214. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016 Jan 01; 22(1):259-67. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. PMID: 26373574.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    215. Actionability and precision oncology. Oncoscience. 2015; 2(10):779-80. Schwaederle M, Kurzrock R. PMID: 26682241.
      View in: PubMed   Mentions:
    216. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015 Sep; 34(3):479-96. Helsten T, Schwaederle M, Kurzrock R. PMID: 26224133.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    217. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. PMID: 26304871.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    218. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract. 2015 Nov; 11(6):442-9. Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R. PMID: 26243651.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    219. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. PMID: 26155941.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    220. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):597-603. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. PMID: 26210681.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    221. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. PMID: 26169970.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    222. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. Semin Oncol. 2015 Oct; 42(5):731-9. Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. PMID: 26433554.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    223. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat Rev. 2015 Nov; 41(9):761-6. Khemlina G, Ikeda S, Kurzrock R. PMID: 26210103.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    224. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2015 Jul; 53(7):563-72. Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. PMID: 26073352.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    225. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. JAMA Oncol. 2015 Jul; 1(4):542. Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH. PMID: 26181268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    226. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. PMID: 26244164.
      View in: PubMed   Mentions:
    227. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treat Rev. 2015 Sep; 41(8):699-706. Ikeda S, Hansel DE, Kurzrock R. PMID: 26138514.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    228. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. PMID: 25944621.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    229. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. PMID: 26054632.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    230. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle. 2015; 14(14):2355-61. Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. PMID: 26030731.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    231. Multiple gene aberrations and breast cancer: lessons from super-responders. BMC Cancer. 2015 May 29; 15:442. Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. PMID: 26021831.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    232. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. PMID: 25990659.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    233. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. PMID: 25980577.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    234. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015; 14(13):2121-8. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. PMID: 25950492.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    235. The checklist: BEST medical center employment requirements 2015. Clin Dermatol. 2015 Jul-Aug; 33(4):493-7. Cohen PR, Kurzrock R. PMID: 26051067.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    236. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. PMID: 25902899.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    237. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. PMID: 25908602.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    238. Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. Dermatol Ther (Heidelb). 2015 Jun; 5(2):129-43. Cohen PR, Kurzrock R. PMID: 25876211.
      View in: PubMed   Mentions:
    239. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. PMID: 25878190.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    240. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun; 14(6):1488-94. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25852059.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    241. Meir Wetzler, MD. Cancer. 2015 Jul 01; 121(13):2106-7. Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM. PMID: 25832851.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    242. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. PMID: 25822109.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    243. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20; 6(8):6029-39. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. PMID: 25760241.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    244. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. PMID: 25806091.
      View in: PubMed   Mentions: 6     Fields:    
    245. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015 Mar 10; 6(7):4553-61. Heestand GM, Kurzrock R. PMID: 25714017.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    246. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015 Mar; 34(1):157-64. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. PMID: 25712293.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    247. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. J Med Case Rep. 2015 Feb 28; 9:45. Mohammed A, Janku F, Qi M, Kurzrock R. PMID: 25884809.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    248. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25596748.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    249. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015 Apr; 14(4):847-56. Patel SP, Kurzrock R. PMID: 25695955.
      View in: PubMed   Mentions: 269     Fields:    Translation:HumansAnimals
    250. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015 Feb 18; 15:61. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. PMID: 25886620.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    251. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3). Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. PMID: 25688104.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    252. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. PMID: 25680763.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    253. VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Res. 2015 Apr 01; 75(7):1187-90. Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R. PMID: 25672981.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    254. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. PMID: 25666183.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    255. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-8. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. PMID: 25669829.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    256. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med. 2015 Feb; 19(103):101-8. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. PMID: 25725224.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    257. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015 Feb; 19(103):109-16. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. PMID: 25725225.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    258. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2015 Jan 20; 6(2):592-603. Munoz J, Wheler JJ, Kurzrock R. PMID: 25595907.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    259. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    260. VEGF and dual-EGFR inhibition in colorectal cancer. Cell Cycle. 2015; 14(8):1129-30. Falchook GS, Kurzrock R. PMID: 25845022.
      View in: PubMed   Mentions: 4     Fields:    
    261. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. PMID: 25285888.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    262. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle. 2015; 14(11):1730-7. Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. PMID: 25928476.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    263. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle. 2015; 14(14):2219-21. Kurzrock R, Giles FJ. PMID: 26030337.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    264. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 2015; 14(21):3434-40. Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. PMID: 26467427.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    265. Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase. J Pers Med. 2014 Dec 15; 4(4):475-88. Geifman N, Haviv I, Kurzrock R, Rubin E. PMID: 25563458.
      View in: PubMed   Mentions:
    266. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med. 2014 Dec; 18(101):323-30. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. PMID: 25549703.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    267. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec; 18(101):331-9. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. PMID: 25549704.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    268. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev. 2014 Dec; 33(4):1109-24. Randall JM, Millard F, Kurzrock R. PMID: 25365943.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    269. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 2014 Nov 30; 5(22):11154-67. Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. PMID: 25525888.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    270. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. PMID: 25426553.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    271. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. PMID: 25373733.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    272. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. PMID: 25363205.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    273. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. PMID: 25361808.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    274. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014; 1(10):614-623. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. PMID: 25593991.
      View in: PubMed   Mentions:
    275. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. PMID: 25323060.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    276. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. PMID: 25326232.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    277. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014 Dec 15; 74(24):7181-4. Wheler J, Lee JJ, Kurzrock R. PMID: 25326492.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    278. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015 Jan; 5(1):64-71. Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. PMID: 25324352.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    279. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. PMID: 25313136.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    280. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. PMID: 25316815.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    281. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. PMID: 25253784.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    282. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676. Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R. PMID: 25119929.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    283. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. PMID: 25594061.
      View in: PubMed   Mentions:
    284. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. PMID: 25587555.
      View in: PubMed   Mentions:
    285. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. PMID: 25087088.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    286. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014; 6(1):13. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II. PMID: 25024751.
      View in: PubMed   Mentions: 4     Fields:    
    287. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. PMID: 24987059.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    288. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2014 Sep 01; 20(17):4449-58. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. PMID: 24958809.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    289. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. PMID: 25003695.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    290. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014 Jun 15; 5(11):3607-10. Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. PMID: 25003820.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    291. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. PMID: 24919855.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    292. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014 Dec; 32(6):1181-7. Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. PMID: 24879333.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    293. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. PMID: 24912489.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    294. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. PMID: 24931142.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    295. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014 Aug; 40(7):883-91. Liu S, Kurzrock R. PMID: 24867380.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    296. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. PMID: 24811890.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    297. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):125-30. Bendell JC, Hong DS, Burris HA, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. PMID: 24819685.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    298. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc. 2014 Jul; 89(7):985-96. Munoz J, Janku F, Cohen PR, Kurzrock R. PMID: 24814521.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    299. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. PMID: 24797821.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    300. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. PMID: 24778042.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    301. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. PMID: 24764123.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    302. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. PMID: 24746841.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    303. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. PMID: 24752867.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    304. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009. Clin Cancer Res. 2014 Jul 01; 20(13):3364-70. Morgan-Linnell SK, Stewart DJ, Kurzrock R. PMID: 24737548.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    305. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. PMID: 24742823.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    306. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. PMID: 24742900.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    307. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014 Apr; 34(4):1939-45. Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R. PMID: 24692729.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    308. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. PMID: 24668327.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    309. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014 Jul; 40(6):770-80. Yan M, Parker BA, Schwab R, Kurzrock R. PMID: 24656976.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    310. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2192-204. Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R. PMID: 24563479.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    311. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. PMID: 24586081.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    312. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. PMID: 24435060.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    313. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. PMID: 24440717.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    314. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J. 2014 Jan 15; 20(1):21241. Cohen PR, Kurzrock R. PMID: 24456945.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    315. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J. 2014 Jan 15; 20(1):21242. Anzalone CL, Cohen PR, Kurzrock R, Cortes JE. PMID: 24456946.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    316. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 2014 Jan 15; 5(1):67-77. Schroeder RD, Angelo LS, Kurzrock R. PMID: 24393766.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    317. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics. 2014 Jan 09; 6(1):2. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R. PMID: 24401732.
      View in: PubMed   Mentions: 5     Fields:    
    318. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. PMID: 24390424.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    319. A cancer trial scandal and its regulatory backlash. Nat Biotechnol. 2014 Jan; 32(1):27-31. Kurzrock R, Kantarjian H, Stewart DJ. PMID: 24406925.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    320. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. PMID: 25593979.
      View in: PubMed   Mentions:
    321. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. PMID: 24335388.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    322. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. PMID: 24306314.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    323. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014 Jun; 32(3):436-44. Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. PMID: 24258465.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    324. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. PMID: 24365125.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    325. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8. Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. PMID: 24190980.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    326. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol. 2013 Dec; 24(12):3004-11. Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. PMID: 24158411.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    327. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. PMID: 24153239.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    328. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck. 2014 Mar; 36(3):E25-7. Falchook GS, Lippman SM, Bastida CC, Kurzrock R. PMID: 23852769.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    329. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. PMID: 24101145.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    330. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. PMID: 24092809.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    331. Equipoise abandoned? Randomization and clinical trials. Ann Oncol. 2013 Oct; 24(10):2471-4. Kurzrock R, Stewart DJ. PMID: 24072520.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    332. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. PMID: 24089446.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    333. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. PMID: 24634931.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    334. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol. 2013 Nov; 72(5):1089-96. Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. PMID: 24057042.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    335. Genetics on a WHIM. Br J Haematol. 2014 Jan; 164(1):15-23. Al Ustwani O, Kurzrock R, Wetzler M. PMID: 24111611.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    336. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct; 12(10):2167-75. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. PMID: 23963360.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    337. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. PMID: 23907406.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    338. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PLoS One. 2013; 8(7):e68985. Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM. PMID: 23922674.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    339. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle. 2013 Dec; 4(4):259-65. Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. PMID: 23893509.
      View in: PubMed   Mentions: 5     Fields:    
    340. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. PMID: 23873691.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    341. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. PMID: 23867127.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    342. Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. Eur J Radiol. 2013 Oct; 82(10):1811-8. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. PMID: 23769187.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    343. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. PMID: 23756764.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    344. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013 Jul 10; 31(20):e351-2. Munoz J, Schlette E, Kurzrock R. PMID: 23733763.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    345. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol. 2013 Jul 10; 31(20):e360-3. Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. PMID: 23733774.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    346. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 2013 Jun; 4(6):884-9. Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. PMID: 23800680.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    347. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. PMID: 23765114.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    348. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. PMID: 23676418.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    349. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 01; 19(13):3659-70. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. PMID: 23659971.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    350. The Karabus affair speaks to larger issues for American academic and medical centers. Clin Dermatol. 2013 May-Jun; 31(3):325-6. Zwelling LA, Kurzrock R, Cohen PR, Levin B, Parish LC. PMID: 23608452.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    351. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. PMID: 23670029.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    352. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. PMID: 23800712.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    353. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833. Jain RK, Lee JJ, Hong D, Kurzrock R. PMID: 23628598.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    354. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. PMID: 23609829.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    355. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer. 2013 Apr 16; 13:193. Stewart DJ, Kurzrock R. PMID: 23587187.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    356. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. PMID: 23576709.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    357. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70. Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R. PMID: 23455881.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    358. Compliance in early-phase cancer clinical trials research. Oncologist. 2013; 18(3):308-13. Kurzrock R, Stewart DJ. PMID: 23457001.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    359. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget. 2013 Mar; 4(3):463-73. Janku F, Huang HJ, Angelo LS, Kurzrock R. PMID: 23531874.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    360. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013 Mar; 149(3):322-6. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, Hong DS, Kurzrock R. PMID: 23552670.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    361. Dodging a dogma: is treating beyond progression beneficial? Cancer Chemother Pharmacol. 2013 May; 71(5):1385-6. Naing A, Kurzrock R. PMID: 23443308.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    362. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May; 49(7):1521-9. Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. PMID: 23433846.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    363. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 05; 108(4):826-30. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. PMID: 23412108.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    364. Unilateral proptosis. JAMA. 2013 Feb 13; 309(6):605-6. Munoz J, Kurzrock R. PMID: 23403685.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    365. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013 Sep; 8(3):183-188. Janku F, Wheler JJ, Hong DS, Kurzrock R. PMID: 23400451.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    366. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013 Feb; 4(2):310-5. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R. PMID: 23470635.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    367. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. PMID: 23328556.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    368. Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. AJR Am J Roentgenol. 2013 Feb; 200(2):W155-62. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. PMID: 23345379.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    369. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. 2013 Aug; 31(4):967-73. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. PMID: 23361621.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    370. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. PMID: 23358976.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    371. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396. Jain RK, Lee JJ, Hong D, Kurzrock R. PMID: 23451354.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    372. A tale of two histiocytic disorders. Oncologist. 2013; 18(1):2-4. Janku F, Munoz J, Subbiah V, Kurzrock R. PMID: 23299771.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    373. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. PMID: 23435217.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    374. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book. 2013; 127-34. Munoz J, Swanton C, Kurzrock R. PMID: 23714478.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    375. Warning signal: unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. Clin Dermatol. 2013 Jan-Feb; 31(1):128-30. Cohen PR, Kurzrock R, Parish LC. PMID: 23245984.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    376. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. PMID: 23391555.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    377. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorg Med Chem. 2013 Feb 15; 21(4):932-9. Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. PMID: 23294827.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    378. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PMID: 23248156.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    379. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther. 2012 Dec; 11(12):2549-55. Westin JR, Kurzrock R. PMID: 23204432.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    380. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013 Jun; 39(4):375-87. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. PMID: 23199899.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    381. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. PMID: 23179336.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    382. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. PMID: 23143207.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    383. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. PMID: 23139256.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    384. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PMID: 23066039.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    385. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012 Nov 15; 18(22):6356-63. Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. PMID: 23014530.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    386. Targeted therapy in rare cancers--adopting the orphans. Nat Rev Clin Oncol. 2012 Nov; 9(11):631-42. Munoz J, Kurzrock R. PMID: 22965154.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    387. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. PMID: 22966018.
      View in: PubMed   Mentions: 151     Fields:    Translation:Humans
    388. The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides. J Clin Aesthet Dermatol. 2012 Sep; 5(9):27-36. Cohen PR, Prieto VG, Piha-Paul SA, Kurzrock R. PMID: 23050032.
      View in: PubMed   Mentions:
    389. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012 Sep 25; 107(7):1093-9. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R, Banerji U. PMID: 22935583.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    390. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. PMID: 22927482.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    391. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 2012 Nov; 11(11):2483-94. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. PMID: 22914438.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    392. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther. 2012 Nov; 11(11):2541-6. Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. PMID: 22914439.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    393. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA. PMID: 22805291.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    394. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. PMID: 22805292.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansCTClinical Trials
    395. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. PMID: 22778314.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    396. Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. J Comput Assist Tomogr. 2012 Jul-Aug; 36(4):388-93. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. PMID: 22805665.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    397. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-3. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. PMID: 22745218.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    398. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. PMID: 22693357.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    399. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. PMID: 22689801.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    400. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012 Dec 15; 118(24):6144-51. Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. PMID: 22674635.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    401. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. PMID: 22580643.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    402. Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. Int J Dermatol. 2012 Jun; 51(6):631-46; quiz 643-4, 646. Paul LJ, Cohen PR, Kurzrock R. PMID: 22607279.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    403. Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med. 2012 Jun; 13(73):405-15. Subbiah V, Kurzrock R. PMID: 22742646.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    404. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. PMID: 22675430.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    405. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. PMID: 22634319.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    406. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012 May 19; 379(9829):1893-901. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. PMID: 22608338.
      View in: PubMed   Mentions: 248     Fields:    Translation:HumansCTClinical Trials
    407. Cutaneous Castleman disease. Br J Haematol. 2012 Jun; 157(6):652. Munoz J, Naing A, Qi M, Kurzrock R. PMID: 22533925.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    408. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. PMID: 22537607.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    409. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 01; 30(19):2348-53. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. PMID: 22529266.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCellsCTClinical Trials
    410. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. PMID: 22487539.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    411. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012 Jun; 11(6):1221-5. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. PMID: 22491798.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    412. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. PMID: 22465830.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    413. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. PMID: 22452943.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    414. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-7. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. PMID: 22377564.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    415. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. PMID: 22355009.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsCTClinical Trials
    416. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PMID: 22271473.
      View in: PubMed   Mentions: 172     Fields:    Translation:Humans
    417. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. PMID: 22229660.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    418. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012; 7(1):e29330. Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. PMID: 22235285.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    419. Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes. Am Soc Clin Oncol Educ Book. 2012; 179-85. Westin JR, Kantarjian H, Kurzrock R. PMID: 24451731.
      View in: PubMed   Mentions: 2     Fields:    
    420. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 May; 69(5):1117-26. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. PMID: 22205203.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    421. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012 Feb; 11(2):308-16. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. PMID: 22203732.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    422. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8. Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. PMID: 22203760.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    423. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012 Jan; 95(1):1-2. Munoz J, Hong D, Kurzrock R. PMID: 22170230.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    424. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. PMID: 22039425.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    425. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One. 2011; 6(10):e26060. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. PMID: 22022506.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    426. Advancing the scope of nursing practice: hepatic arterial catheter removal. Clin J Oncol Nurs. 2011 Oct; 15(5):465-8. Barosh BA, Holmes C, Keerikattu LM, Manappurathu MS, Segovia JH, Hasen PC, Pai SV, Lobiondo-Wood G, Kurzrock R. PMID: 21951733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    427. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol. 2011 Dec; 32(11):2126-31. Sedrak P, Ketonen L, Hou P, Guha-Thakurta N, Williams MD, Kurzrock R, Debnam JM. PMID: 21960492.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    428. Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? Expert Opin Investig Drugs. 2011 Nov; 20(11):1471-7. Subbiah V, Angelo LS, Kurzrock R. PMID: 21936711.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    429. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther. 2011 Nov; 10(11):2094-103. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. PMID: 21903608.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    430. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. PMID: 21890452.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    431. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1601-12. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. PMID: 21849857.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    432. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. PMID: 21859821.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    433. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. PMID: 21844494.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    434. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 2011 Sep 10; 29(26):e727-30. Piha-Paul SA, Cohen PR, Kurzrock R. PMID: 21844496.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    435. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. PMID: 21831956.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    436. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. PMID: 21823111.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    437. The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol. 2011 08 02; 8(9):562-6. Garrido-Laguna I, Hidalgo M, Kurzrock R. PMID: 21808269.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    438. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PMID: 21829508.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    439. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology. 2011 Sep; 260(3):762-70. Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R, Charnsangavej C. PMID: 21788525.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    440. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. PMID: 21750201.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    441. Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol. 2011 Jul; 197(1):113-21. Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Charnsangavej C, Kurzrock R. PMID: 21701018.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    442. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011 Jul; 23(4):352-60. Subbiah V, Kurzrock R. PMID: 21519259.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    443. Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One. 2011; 6(6):e21250. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. PMID: 21731684.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    444. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Jan; 69(1):165-72. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS. PMID: 21638123.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    445. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. PMID: 21606412.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCTClinical Trials
    446. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 May 17; 8(9):528-39. Janku F, McConkey DJ, Hong DS, Kurzrock R. PMID: 21587219.
      View in: PubMed   Mentions: 217     Fields:    Translation:HumansAnimalsCells
    447. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. PMID: 21571911.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    448. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. PMID: 21538342.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    449. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1507-16. Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. PMID: 21499896.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    450. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. PMID: 21482991.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    451. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011 Apr 06; 6(4):e18424. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P, Kurzrock R. PMID: 21494688.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    452. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011; 16(4):497-511. El-Osta HE, Kurzrock R. PMID: 21441298.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    453. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. PMID: 21415223.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    454. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. PMID: 21339262.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    455. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J Cancer. 2011 Feb 10; 2:81-9. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. PMID: 21326629.
      View in: PubMed   Mentions:
    456. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. PMID: 21289252.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    457. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 2011 Feb 01; 12(1):63-7. Cohen PR, Escudier SM, Kurzrock R. PMID: 20726623.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    458. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol. 2011 Apr 20; 29(12):e333-5. Piha-Paul SA, Hong DS, Kurzrock R. PMID: 21263090.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    459. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PMID: 21216929.
      View in: PubMed   Mentions: 144     Fields:    Translation:Humans
    460. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther. 2011 Jan; 10(1):209-17. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. PMID: 21220503.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    461. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. PMID: 21208846.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    462. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther. 2010 Dec; 9(12):3410-9. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. PMID: 21159616.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    463. Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs. 2010 Dec; 19(12):1569-80. Tsimberidou AM, Chandhasin C, Kurzrock R. PMID: 21083522.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    464. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. PMID: 21472713.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    465. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010 Dec; 9(12):3254-66. Srivastava RK, Kurzrock R, Shankar S. PMID: 21041383.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    466. Development of curcumin as an epigenetic agent. Cancer. 2010 Oct 15; 116(20):4670-6. Fu S, Kurzrock R. PMID: 20597137.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    467. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 01; 16(23):5883-91. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. PMID: 20947515.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    468. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. PMID: 20941597.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    469. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs. 2012 Feb; 30(1):327-34. Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM. PMID: 20842406.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    470. Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study. Cancer. 2010 Sep 15; 116(18):4402-9. Hui D, Parsons H, Nguyen L, Palla SL, Yennurajalingam S, Kurzrock R, Bruera E. PMID: 20564164.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    471. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. PMID: 20564148.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    472. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. PMID: 20737567.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    473. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010 Nov 01; 28(31):e633-6. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. PMID: 20733125.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    474. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug 10; 28(23):3701-8. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. PMID: 20625121.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    475. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010 Aug 20; 28(24):e415. Subbiah V, Trent JC, Kurzrock R. PMID: 20567010.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    476. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol. 2010 Jul; 7(7):401-14. Janku F, Stewart DJ, Kurzrock R. PMID: 20551945.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    477. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 01; 16(15):4031-7. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. PMID: 20525754.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    478. Salirasib in the treatment of pancreatic cancer. Future Oncol. 2010 Jun; 6(6):885-91. Bustinza-Linares E, Kurzrock R, Tsimberidou AM. PMID: 20528225.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    479. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther. 2010 Jun; 9(6):1485-8. El-Osta H, Janku F, Kurzrock R. PMID: 20501803.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    480. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010 Jun 10; 28(17):2839-46. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. PMID: 20458040.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCTClinical Trials
    481. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010 Jun 10; 28(17):2925-35. Stewart DJ, Whitney SN, Kurzrock R. PMID: 20406924.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    482. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010 Apr 15; 16(8):2458-65. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L. PMID: 20371689.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    483. Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer. 2010 Apr; 9(2):E1-4. Naing A, Kurzrock R. PMID: 20378496.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    484. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. PMID: 20347123.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    485. Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review. Mol Oncol. 2010 Aug; 4(4):306-8. Chintala L, Kurzrock R. PMID: 20346742.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    486. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. PMID: 20204368.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    487. Evaluation of liposomal curcumin cytochrome p450 metabolism. Anticancer Res. 2010 Mar; 30(3):811-4. Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA. PMID: 20393001.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    488. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. PMID: 20145187.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    489. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res. 2010 Feb 15; 16(4):1256-63. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. PMID: 20145186.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    490. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010; 15(2):130-41. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. PMID: 20139170.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    491. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol. 2010 Feb; 194(2):W134-40. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. PMID: 20093564.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    492. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. PMID: 20133258.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    493. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist. 2010; 15(1):37-50. Rodon J, Perez J, Kurzrock R. PMID: 20080862.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    494. Juice plus or toxicity plus. Am J Med. 2010 Jan; 123(1):e1-2. Naing A, Aaron J, Kurzrock R. PMID: 20102976.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    495. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Jan; 65(2):235-41. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. PMID: 19484470.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    496. </